DexCom, Inc. $DXCM Shares Bought by Bokf Na

Key Points

• Bokf Na increased its stake in DexCom by 175.7% in Q4, buying 22,505 shares to hold 35,314 shares valued at about $2.34 million, while other institutions (e.g., Nordea, Gradient) also added shares and institutional ownership stands at 97.75%.
• DexCom beat quarterly estimates with EPS $0.56 versus $0.47 expected and revenue of $1.19 billion (up 15% year-over-year), showing continued top-line and profitability improvement.
• Analysts maintain a generally positive view—consensus rating is “Moderate Buy” with an average price target of about $83.50 (individual targets range roughly $75–$100).

Bokf Na grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 175.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,314 shares of the medical device company's stock after purchasing an additional 22,505 shares during the period. Bokf Na's holdings in DexCom were worth $2,344,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gradient Investments LLC grew its position in shares of DexCom by 13.8% during the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company's stock worth $22,035,000 after acquiring an additional 40,343 shares during the last quarter. Nordea Investment Management AB grew its position in shares of DexCom by 118.6% during the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company's stock worth $16,988,000 after acquiring an additional 137,986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company's stock worth $14,269,000 after acquiring an additional 21,352 shares during the last quarter. NEOS Investment Management LLC grew its position in shares of DexCom by 58.7% during the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company's stock worth $11,842,000 after acquiring an additional 65,066 shares during the last quarter. Finally, Peterson Wealth Services grew its position in shares of DexCom by 423.6% during the third quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company's stock worth $1,947,000 after acquiring an additional 23,410 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares of the company's stock, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.28% of the company's stock.

DexCom Stock Up 0.9%

DXCM stock opened at $60.91 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a market capitalization of $23.50 billion, a price-to-earnings ratio of 26.03, a price-to-earnings-growth ratio of 1.04 and a beta of 1.40. The firm's 50-day moving average is $65.10 and its two-hundred day moving average is $66.29. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the firm earned $0.32 EPS. DexCom's revenue was up 15.0% on a year-over-year basis. On average, analysts forecast that DexCom, Inc. will post 2.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Mizuho set a $75.00 price target on shares of DexCom in a research report on Friday, May 1st. BTIG Research restated a "buy" rating and set a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Canaccord Genuity Group set a $100.00 price target on shares of DexCom and gave the stock a "buy" rating in a research report on Friday, May 1st. Weiss Ratings raised shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, March 4th. Finally, Raymond James Financial set a $81.00 price objective on shares of DexCom in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $83.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.